GeneDx Holdings Corp.

NasdaqGS:WGS Stok Raporu

Piyasa değeri: US$1.3b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

GeneDx Holdings Yönetim

Yönetim kriter kontrolleri 3/4

GeneDx Holdings' CEO'su Katherine Stueland, May2022 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 3.58M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.9% maaş ve 81.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.39% ine doğrudan sahiptir ve bu hisseler $ 4.40M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 3.3 yıldır.

Anahtar bilgiler

Katherine Stueland

İcra Kurulu Başkanı

US$3.6m

Toplam tazminat

CEO maaş yüzdesi18.9%
CEO görev süresi2.4yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi1yrs
Yönetim Kurulu ortalama görev süresi3.3yrs

Son yönetim güncellemeleri

Recent updates

After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Oct 04
After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

Aug 29
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform

Aug 19

Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

Jul 27
Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22
The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20
Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02
Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01
Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

CEO Tazminat Analizi

Katherine Stueland'un ücretlendirmesi GeneDx Holdings'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$117m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$4mUS$675k

-US$176m

Sep 30 2023n/an/a

-US$459m

Jun 30 2023n/an/a

-US$494m

Mar 31 2023n/an/a

-US$533m

Dec 31 2022US$12mUS$454k

-US$549m

Tazminat ve Piyasa: Katherine 'nin toplam tazminatı ($USD 3.58M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Katherine 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Katherine Stueland (48 yo)

2.4yrs

Görev süresi

US$3,575,335

Tazminat

Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Katherine Stueland
President2.4yrsUS$3.58m0.39%
$ 5.2m
Kevin Feeley
Chief Financial Officer2.2yrsUS$1.57m0.17%
$ 2.2m
Karen Ponchner
Head of Operationsless than a yearVeri yokVeri yok
Eric Olivares
Chief Product & Technology Officerless than a yearVeri yokVeri yok
Jami Biliboaca
Head of People Strategyless than a yearVeri yokVeri yok
Paul Kruszka
Chief Medical Officer2.4yrsVeri yokVeri yok
Melanie Duquette
Chief Growth Officer1.1yrsVeri yokVeri yok
Sabrina Dunbar
Chief of Staffno dataVeri yokVeri yok
Britt Johnson
Head of Medical Affairsless than a yearVeri yokVeri yok

1.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: WGS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Katherine Stueland
President2.4yrsUS$3.58m0.39%
$ 5.2m
Joshua Ruch
Independent Director6.9yrsUS$207.98k0.72%
$ 9.7m
Richard Pfenniger
Director2.5yrsUS$192.98k0.10%
$ 1.4m
Keith Meister
Independent Director2.8yrsUS$207.98k0.027%
$ 359.0k
Eli Casdin
Independent Director4.3yrsUS$200.48k0.028%
$ 378.3k
Jason Ryan
Chairman of the Board3.3yrsUS$992.46k0.70%
$ 9.4m
Emily Leproust
Independent Director4.1yrsUS$206.73k0.031%
$ 416.1k

3.3yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: WGS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).